Novaliq raises €13.9m from Dievini Hopp

The latest funding from Dievini takes the total capital committed to Novaliq since 2007 to €27.1m. The VC is the sole backer of the firm, having completed five funding rounds for the company. 

The company intends to use the fresh funding to further the clinical development of its products and extend its technology platform. The company intends to become cash positive by 2016, Bernhard Günther, Novaliq CEO, told unquote".

Dievini is a life and health sciences investor that focuses on companies that develop therapeutics and diagnostics for life-threatening diseases. The firm typically invests in companies based in Germany and Europe.

The investor has backed Novaliq several times, including a €2.3m capital injection in 2011.

Company
Novaliq is a drug delivery company based in the Heidelberg Technology Park, Germany. The firm focuses on the development of a new generation of ocular formulations for poorly soluble drugs. Its ocular formulations are based on semifluorinated alkanes (SFAs), which can be applied as eye drops.

People
Mathias Hothum is managing director of Dievini.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany